In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropin-releasing factor-1 receptor antagonist

Drug Metabolism and Disposition

Volumn 40, Issue 6, 2012, Pages 1093-1103

  Zhou, Lian ^a   Dockens, Randy C ^a   Liu Kreyche, Peggy ^a   Grossman, Scott J ^a   Iyer, Ramaswamy A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BMS 572273; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DPH 123554; DPH 124921; DRUG METABOLITE; PEXACERFONT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHIMPANZEE; CONTROLLED STUDY; DEALKYLATION; DEMETHYLATION; DOG; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HYDROXYLATION; DRUG IDENTIFICATION; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME REGULATION; FEMALE; HAPLORHINI; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER METABOLISM; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; URINARY EXCRETION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CROSS-OVER STUDIES; DOGS; FEMALE; HEPATOCYTES; HUMANS; MACACA FASCICULARIS; MALE; MICE; MICROSOMES, LIVER; PAN TROGLODYTES; PROTEIN BINDING; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SPECIES SPECIFICITY; TRIAZINES;

ANIMALIA; CANIS FAMILIARIS; PAN; RATTUS;

EID: 84862091112     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.043596     Document Type: Article

References (14)

1. Benet LZ (2010) Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System. Basic Clin Pharmacol Toxicol 106:162-167.
2. Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC, Wu X, Gentile KA, Huang SP, Emison E, et al. (2010) Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety 27:417-425.
3. Cubitt HE, Yeo KR, Howgate EM, Rostami-Hodjegan A, and Barter ZE (2011) Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. Xenobiotica 41:623-638.
4. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
5. Fukudo S, Nomura T, and Hongo M (1998) Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut 42:845-849. (Pubitemid 28277227)
6. Gilligan PJ, Clarke T, He L, Lelas S, Li YW, Heman K, Fitzgerald L, Miller K, Zhang G, Marshall A, et al. (2009) Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists. J Med Chem 52:3084-3092.
7. Humphreys WG and Unger SE (2006) Safety assessment of drug metabolites: characterization of chemically stable metabolites. Chem Res Toxicol 19:1564-1649.
8. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed, Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
9. Mahmood I and Balian JD (1996) Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887-895. (Pubitemid 26343083)
10. Owens MJ and Nemeroff CB (1991) Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 43:425-473.
11. Smagin GN and Dunn AJ (2000) The role of CRF receptor subtypes in stress-induced behavioural responses. Eur J Pharmacol 405:199-206.
12. Sweetser S, Camilleri M, Linker Nord SJ, Burton DD, Castenada L, Croop R, Tong G, Dockens R, and Zinsmeister AR (2009) Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome? Am J Physiol Gastrointest Liver Physiol 296:G1299-G1306.
13. Wong H, Grossman SJ, Bai SA, Diamond S, Wright MR, Grace JE Jr, Qian M, He K, Yeleswaram K, and Christ DD (2004) The chimpanzee (Pan troglodytes) as a pharmacokinetic model for selection of drug candidates: model characterization and application. Drug Metab Dispos 32:1359-1369. (Pubitemid 39564555)
14. Zhou L, Lee K, Thakker DR, Boykin DW, Tidwell RR, and Hall JE (2002) Enhanced permeability of the antimicrobial agent 2,5-bis(4-amidinophenyl)furan across Caco-2 cell monolayers via its methylamidoidme prodrug. Pharm Res 19:1689-1695. (Pubitemid 35305521)